Adc Therapeutics SA Schedule 13G passive stakes

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 9.69% of ADC Therapeutics SA's common shares as of June 30, 2026.

BlackRock, Inc. has disclosed beneficial ownership of 5.4% of ADC Therapeutics SA's common stock as of June 30, 2026.

Redmile Group, LLC has completed an internal reorganization of its holdings in ADC Therapeutics SA, maintaining a 9.9 percent beneficial ownership stake while shifting assets to a new subsidiary.

Redmile Group, LLC and Jeremy C. Green report a 9.9% beneficial ownership stake in ADC Therapeutics SA, including shares held through private investment vehicles and warrants.

Prosight Management, LP and affiliated entities have filed an Amendment No. 3 to Schedule 13G, disclosing beneficial ownership of 5.8% of ADC Therapeutics SA's common shares.

Oaktree entities report 4.14% beneficial ownership in ADC Therapeutics SA, while Brookfield entities cease to report beneficial ownership as part of the group.

Redmile Group, LLC and its affiliates have increased their beneficial ownership in ADC Therapeutics SA to 14.0% of common shares outstanding.

Point72 Asset Management, L.P., along with its affiliates and founder Steven A. Cohen, has disclosed a passive 7.0% beneficial ownership stake in ADC Therapeutics SA, totaling 7,831,425 common shares.

An amended Schedule 13G filing reveals Dr. Hans-Peter Wild has consolidated his beneficial ownership in ADC Therapeutics SA to 9.61% following the transfer of interests from former board member Thomas Pfisterer.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.0% passive beneficial ownership stake in ADC Therapeutics SA as of March 31, 2025.

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, disclosing their passive beneficial ownership of 6.2% of ADC Therapeutics SA's common shares as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a beneficial ownership of 5.2% of the common stock of ADC Therapeutics SA as of December 31, 2024.